Skip NavigationSkip to Content
Return Return to Search Results

Preclinical Evaluation of an Anti-CD25 Monoclonal Antibody, 7G7/B6, Armed with the beta-Emitter, Yttrium-90, as a Radioimmunotherapeutic Agent for Treating Lymphoma

  1. Author:
    Zhang, M. L.
    Yao, Z. S.
    Garmestani, K.
    Yu, S.
    Goldman, C. K.
    Paik, C. H.
    Brechbiel, M. W.
    Carrasquillo, J. A.
    Waldmann, T. A.

  2. Author Address

    Zhang, Meili, Yao, Zhengsheng, Garmestani, Kayhan, Goldman, Carolyn K.; Waldmann, Thomas A.] NCI, Metab Branch, NIH, Bethesda, MD 20892 USA. [Brechbiel, Martin W.] NCI, Radiat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Yao, Zhengsheng, Yu, Sarah, Paik, Chang H.; Carrasquillo, Jorge A.] NIH, Ctr Clin, Dept Nucl Med, Bethesda, MD 20892 USA. [Zhang, Meili] NCI Frederick, Lab Anim Sci Program, Frederick, MD USA. [Garmestani, Kayhan] NCI Frederick, Appl Dev Res Support Program, SAIC Frederick Inc, Frederick, MD USA.
    1. Year: 2009
  2. Journal: Cancer Biotherapy and Radiopharmaceuticals
    1. 24
    2. 3
    3. Pages: 303-309
  4. Type of Article: Article
  1. Abstract:

    Objective: Radioimmunotherapy of cancer with radiolabeled antibodies has shown promise. We evaluated an anti-CD25 monoclonal Antibody, 7G7/B6, armed with Y-90 as a potential radioimmunotherapeutic agent for CD25-expressing lymphomas. Materials and Methods: The lymphoma model was established by subcutaneous injection of 1 x 10(7) SUDHL-1 cells into nude mice. The biodistribution of In-111-7G7/B6 and therapeutic studies with Y-90-7G7/B6 were performed in the tumor-bearing mice. Results: Therapy using Y-90-7G7/B6 prolonged survival of the SUDHL-1 lymphoma-bearing mice significantly, as compared with either untreated mice or the mice treated with Y-90-11F11, a radiolabeled isotype-matched control antibody (p < 0.001). All of the mice in the control and the Y-90-11F11 treatment groups died by days 18 and 24, respectively. In contrast, 30% of the mice in the low-dose group (75 mu Ci of Y-90-7G7/B6/mouse) and 75% in the high-dose group (150 mu Ci of Y-90-7G7/B6/mouse) became tumor free and remained healthy for greater than 6 months. Conclusions: Our findings suggested that Y-90-7G7/B6 is a potentially useful radioimmunotherapeutic agent for the treatment of patients with CD25-expressing lymphomas.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1089/cbr.2008.0577
  3. PMID: 19538052

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel